Clinical trial
A Study of Atezolizumab Compared With Docetaxel in Participants With Locally…
NCT02008227 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT02008227 |
|---|---|
| Title | A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy |
| Official title | A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer After Failure With Platinum Containing Chemotherapy |
| Acronym | OAK |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Non-Squamous Non-Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | Atezolizumab, Docetaxel |
| Enrollment | 1,225 |
| Start date | Mar 11, 2014 |
| Primary completion | Jul 7, 2016 |
| Completion | Jan 9, 2019 |
| First posted | Dec 11, 2013 |
| Last update posted | Dec 20, 2019 |
| Countries | Argentina, Austria, Brazil, Canada, Chile, Finland, France, Germany, Greece, Guatemala, Hungary, Italy and 19 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: